Vicente Morales-Oyarvide, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 39 | 2023 | 5349 | 2.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 22 | 2023 | 1724 | 2.230 |
Why?
|
| Adenocarcinoma, Mucinous | 9 | 2021 | 517 | 1.440 |
Why?
|
| Carcinoma, Papillary | 6 | 2017 | 785 | 1.070 |
Why?
|
| Adenocarcinoma | 18 | 2022 | 6313 | 0.900 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 9273 | 0.630 |
Why?
|
| Pancreatic Cyst | 3 | 2019 | 367 | 0.580 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 400 | 0.520 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 442 | 0.450 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2012 | 62 | 0.420 |
Why?
|
| Cystadenoma, Serous | 2 | 2012 | 100 | 0.410 |
Why?
|
| Pancreaticoduodenectomy | 5 | 2017 | 508 | 0.400 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1303 | 0.370 |
Why?
|
| Pancreatitis | 2 | 2015 | 1098 | 0.360 |
Why?
|
| Pancreatic Ducts | 3 | 2017 | 329 | 0.360 |
Why?
|
| Pancreatectomy | 6 | 2020 | 810 | 0.350 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 936 | 0.350 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 2523 | 0.340 |
Why?
|
| Adenocarcinoma, Papillary | 3 | 2021 | 84 | 0.340 |
Why?
|
| Lung Neoplasms | 9 | 2017 | 13245 | 0.320 |
Why?
|
| Neuroendocrine Tumors | 2 | 2014 | 650 | 0.300 |
Why?
|
| Colorectal Neoplasms | 6 | 2021 | 6852 | 0.300 |
Why?
|
| Lymph Nodes | 3 | 2017 | 3485 | 0.290 |
Why?
|
| Insulin | 2 | 2019 | 6578 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 3617 | 0.270 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3069 | 0.260 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2019 | 194 | 0.260 |
Why?
|
| Vitamin D | 2 | 2016 | 3283 | 0.250 |
Why?
|
| Neoplasm Staging | 11 | 2021 | 11152 | 0.250 |
Why?
|
| Survival Rate | 9 | 2019 | 12721 | 0.240 |
Why?
|
| Uterine Neoplasms | 3 | 2018 | 1439 | 0.240 |
Why?
|
| DNA Mismatch Repair | 2 | 2019 | 428 | 0.230 |
Why?
|
| Aged | 45 | 2021 | 168217 | 0.230 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 6821 | 0.220 |
Why?
|
| Leukocytes | 3 | 2021 | 2025 | 0.220 |
Why?
|
| Middle Aged | 47 | 2021 | 219560 | 0.210 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 3840 | 0.200 |
Why?
|
| Heart Failure | 2 | 2023 | 11594 | 0.200 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 58681 | 0.190 |
Why?
|
| Prognosis | 14 | 2023 | 29558 | 0.190 |
Why?
|
| Pancreas | 3 | 2020 | 1676 | 0.190 |
Why?
|
| Diet | 1 | 2019 | 8003 | 0.180 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 12440 | 0.180 |
Why?
|
| CA-19-9 Antigen | 1 | 2020 | 106 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 5818 | 0.170 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 195 | 0.170 |
Why?
|
| Exercise | 1 | 2016 | 5788 | 0.170 |
Why?
|
| Immunohistochemistry | 9 | 2018 | 11070 | 0.170 |
Why?
|
| Female | 50 | 2021 | 390316 | 0.160 |
Why?
|
| Male | 48 | 2021 | 358742 | 0.160 |
Why?
|
| Humans | 66 | 2023 | 758381 | 0.160 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 165 | 0.160 |
Why?
|
| Antibodies | 2 | 2019 | 2420 | 0.160 |
Why?
|
| Epithelioid Cells | 1 | 2018 | 60 | 0.160 |
Why?
|
| Risk Factors | 16 | 2021 | 73806 | 0.150 |
Why?
|
| Exercise Test | 2 | 2023 | 2121 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 380 | 0.150 |
Why?
|
| Mucoproteins | 1 | 2017 | 49 | 0.150 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2018 | 77 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2022 | 830 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 5246 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2504 | 0.140 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 52 | 0.140 |
Why?
|
| Myofibroma | 1 | 2017 | 45 | 0.140 |
Why?
|
| Jews | 1 | 2019 | 364 | 0.140 |
Why?
|
| Adult | 33 | 2021 | 219916 | 0.140 |
Why?
|
| Dietary Sucrose | 1 | 2018 | 243 | 0.130 |
Why?
|
| Antibody Specificity | 2 | 2019 | 1060 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2019 | 276 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2016 | 2249 | 0.130 |
Why?
|
| Sweetening Agents | 1 | 2018 | 290 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2020 | 820 | 0.130 |
Why?
|
| Mutation | 5 | 2018 | 29915 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2018 | 4485 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2019 | 772 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 529 | 0.120 |
Why?
|
| Receptors, Leptin | 1 | 2016 | 350 | 0.120 |
Why?
|
| Immunodominant Epitopes | 1 | 2016 | 240 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Gastroenterostomy | 1 | 2014 | 18 | 0.120 |
Why?
|
| Prospective Studies | 14 | 2021 | 54136 | 0.120 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 344 | 0.120 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2016 | 311 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 3801 | 0.120 |
Why?
|
| Amylases | 1 | 2014 | 169 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2019 | 22031 | 0.110 |
Why?
|
| Survival Analysis | 7 | 2021 | 10112 | 0.110 |
Why?
|
| Cyst Fluid | 1 | 2014 | 83 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2016 | 1086 | 0.110 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 39060 | 0.110 |
Why?
|
| Energy Intake | 2 | 2018 | 2127 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2017 | 9650 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 3227 | 0.110 |
Why?
|
| Beverages | 1 | 2018 | 818 | 0.110 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2943 | 0.100 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 336 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1007 | 0.100 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 715 | 0.100 |
Why?
|
| Leiomyoma | 1 | 2017 | 654 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 2115 | 0.100 |
Why?
|
| Gastroparesis | 1 | 2014 | 136 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2023 | 5460 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 380 | 0.100 |
Why?
|
| ras Proteins | 2 | 2014 | 1049 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 832 | 0.100 |
Why?
|
| Telomerase | 1 | 2016 | 745 | 0.100 |
Why?
|
| Heart Rate | 1 | 2022 | 4166 | 0.090 |
Why?
|
| Taxoids | 1 | 2014 | 668 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5787 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 567 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2015 | 1728 | 0.090 |
Why?
|
| Drainage | 1 | 2016 | 1161 | 0.090 |
Why?
|
| Echocardiography | 1 | 2022 | 4962 | 0.090 |
Why?
|
| Body Composition | 1 | 2019 | 2416 | 0.090 |
Why?
|
| Endosonography | 1 | 2014 | 607 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 1594 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 1725 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1765 | 0.080 |
Why?
|
| Quinazolines | 1 | 2015 | 1360 | 0.080 |
Why?
|
| DNA Helicases | 1 | 2014 | 854 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 1110 | 0.080 |
Why?
|
| Leptin | 1 | 2016 | 1591 | 0.080 |
Why?
|
| Cisplatin | 1 | 2014 | 1645 | 0.080 |
Why?
|
| Fabaceae | 1 | 2008 | 103 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2270 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2825 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2019 | 3299 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2020 | 80170 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 1122 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 2053 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3609 | 0.070 |
Why?
|
| Aspirin | 1 | 2017 | 3132 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 2800 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2895 | 0.060 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 9575 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2016 | 12096 | 0.060 |
Why?
|
| Postoperative Complications | 4 | 2016 | 15638 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 1613 | 0.060 |
Why?
|
| Carcinoma | 1 | 2016 | 2330 | 0.060 |
Why?
|
| Incidence | 6 | 2019 | 21273 | 0.060 |
Why?
|
| Acute Disease | 1 | 2015 | 7225 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2008 | 489 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 551 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 4902 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7377 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3586 | 0.060 |
Why?
|
| Disease Progression | 3 | 2018 | 13468 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 17768 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2018 | 64379 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20500 | 0.060 |
Why?
|
| Smoking | 2 | 2018 | 9042 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5098 | 0.050 |
Why?
|
| Cytokines | 1 | 2018 | 7338 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 4876 | 0.050 |
Why?
|
| Mexico | 2 | 2015 | 758 | 0.050 |
Why?
|
| Proteins | 1 | 2017 | 6026 | 0.050 |
Why?
|
| Hospitals, General | 2 | 2017 | 795 | 0.050 |
Why?
|
| United States | 9 | 2021 | 72140 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 10719 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 9160 | 0.050 |
Why?
|
| Claudins | 1 | 2023 | 115 | 0.050 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 12096 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 1893 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 15225 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18357 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 2244 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 12951 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15773 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 7985 | 0.040 |
Why?
|
| Young Adult | 5 | 2017 | 58808 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2023 | 8506 | 0.040 |
Why?
|
| Biopsy | 3 | 2016 | 6768 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4106 | 0.040 |
Why?
|
| Ornithine | 1 | 2017 | 79 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1930 | 0.040 |
Why?
|
| Health Surveys | 2 | 2017 | 4060 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2023 | 1846 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 12076 | 0.030 |
Why?
|
| Phenotype | 3 | 2023 | 16534 | 0.030 |
Why?
|
| Cotinine | 1 | 2017 | 203 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 316 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2020 | 41252 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2018 | 354 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3615 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 314 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6493 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 20052 | 0.030 |
Why?
|
| Obesity | 1 | 2017 | 12870 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2015 | 216 | 0.030 |
Why?
|
| Latin America | 1 | 2015 | 405 | 0.030 |
Why?
|
| Boston | 2 | 2017 | 9304 | 0.030 |
Why?
|
| Arginine | 1 | 2017 | 933 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 607 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 2013 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 719 | 0.030 |
Why?
|
| Mitosis | 1 | 2018 | 1191 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2016 | 370 | 0.030 |
Why?
|
| Telomere | 1 | 2019 | 931 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11709 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2716 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1705 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2023 | 4159 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 611 | 0.030 |
Why?
|
| Massachusetts | 2 | 2016 | 8823 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2019 | 23883 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 788 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 1228 | 0.030 |
Why?
|
| California | 1 | 2016 | 1419 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 714 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2012 | 83 | 0.020 |
Why?
|
| Animals | 4 | 2017 | 167777 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2821 | 0.020 |
Why?
|
| Time Factors | 3 | 2017 | 39873 | 0.020 |
Why?
|
| Patient Selection | 2 | 2014 | 4244 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2016 | 1326 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 651 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1840 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3425 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2018 | 12876 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4839 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13276 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 2378 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 1722 | 0.020 |
Why?
|
| Carbon Tetrachloride | 1 | 2008 | 72 | 0.020 |
Why?
|
| Risk | 1 | 2020 | 9599 | 0.020 |
Why?
|
| Nurses | 1 | 2017 | 2467 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2008 | 127 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 5629 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 36285 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5031 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2016 | 2621 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 1573 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2008 | 295 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6895 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 4641 | 0.020 |
Why?
|
| Flavonoids | 1 | 2008 | 443 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14641 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2008 | 616 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 4901 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2008 | 1844 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2012 | 2772 | 0.010 |
Why?
|
| Mitochondria | 1 | 2017 | 3584 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2907 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14481 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5484 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14354 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9405 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2012 | 1990 | 0.010 |
Why?
|
| Length of Stay | 1 | 2014 | 6439 | 0.010 |
Why?
|
| Recurrence | 1 | 2013 | 8426 | 0.010 |
Why?
|
| Comorbidity | 1 | 2015 | 10495 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 13591 | 0.010 |
Why?
|
| Pyridines | 1 | 2012 | 2860 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 81107 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4023 | 0.010 |
Why?
|
| Antioxidants | 1 | 2008 | 1662 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10146 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2020 | 23341 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 7502 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 23681 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 21017 | 0.010 |
Why?
|
| Child | 1 | 2017 | 79813 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 87888 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 18125 | 0.000 |
Why?
|